



Clinical trial results:

A multicenter, international, randomized, parallel group, double blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcome study with LINagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELINA

Summary

| | |
|--------------------------|-------------------------------|
| EudraCT number | 2011-004148-23 |
| Trial protocol | PT GB CZ NL HU ES PL BG HR DE |
| Global end of trial date | 18 January 2018 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v2 (current) |
| This version publication date | 14 November 2021 |
| First version publication date | 02 February 2019 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | 1218.22 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01897532 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Boehringer Ingelheim |
| Sponsor organisation address | Binger Strasse 173, Ingelheim am Rhein, Germany, 55216 |
| Public contact | QRPE Processes and Systems Coordination Clinical Trial Information Disclosure,, Boehringer Ingelheim, +001 8002430127, clintrriage.rdg@boehringer-ingelheim.com |
| Scientific contact | QRPE Processes and Systems Coordination Clinical Trial Information Disclosure, Boehringer Ingelheim, +001 8002430127, clintrriage.rdg@boehringer-ingelheim.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 29 March 2018 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 18 January 2018 |
| Global end of trial reached? | Yes |
| Global end of trial date | 18 January 2018 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to demonstrate non-inferiority (non-inferiority margin of 1.3 for the upper limit of the 95% confidence interval) of treatment with linagliptin in comparison to placebo (as add-on therapy to standard of care) with respect to time to first occurrence of any of the adjudicated components of the primary composite endpoint (i.e. cardiovascular [CV] death, non-fatal stroke or non-fatal myocardial infarction [MI]) in patients with type 2 diabetes mellitus (T2DM) at high risk of CV events. If non-inferiority was demonstrated, then the primary composite endpoint was to be tested for superiority. The other objective, to assess the impact of treatment with respect to the composite renal endpoint (i.e. renal death, sustained end-stage renal disease [ESRD], sustained decrease in estimated glomerular filtration rate [eGFR] $\geq 40\%$ from baseline), was to be investigated separately with a test on superiority.

Protection of trial subjects:

Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 29 July 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------------|
| Country: Number of subjects enrolled | Argentina: 1187 |
| Country: Number of subjects enrolled | Brazil: 1658 |
| Country: Number of subjects enrolled | Bulgaria: 165 |
| Country: Number of subjects enrolled | Canada: 221 |
| Country: Number of subjects enrolled | Chile: 156 |
| Country: Number of subjects enrolled | China: 151 |
| Country: Number of subjects enrolled | Colombia: 195 |
| Country: Number of subjects enrolled | Croatia: 66 |
| Country: Number of subjects enrolled | Czechia: 116 |
| Country: Number of subjects enrolled | Germany: 37 |
| Country: Number of subjects enrolled | Hungary: 231 |
| Country: Number of subjects enrolled | Israel: 197 |
| Country: Number of subjects enrolled | Japan: 101 |
| Country: Number of subjects enrolled | Malaysia: 254 |
| Country: Number of subjects enrolled | Mexico: 849 |

| | |
|--------------------------------------|-------------------------|
| Country: Number of subjects enrolled | Netherlands: 82 |
| Country: Number of subjects enrolled | Poland: 1040 |
| Country: Number of subjects enrolled | Portugal: 90 |
| Country: Number of subjects enrolled | Romania: 524 |
| Country: Number of subjects enrolled | Russian Federation: 517 |
| Country: Number of subjects enrolled | South Africa: 458 |
| Country: Number of subjects enrolled | Korea, Republic of: 169 |
| Country: Number of subjects enrolled | Spain: 221 |
| Country: Number of subjects enrolled | Taiwan: 151 |
| Country: Number of subjects enrolled | Ukraine: 878 |
| Country: Number of subjects enrolled | United Kingdom: 216 |
| Country: Number of subjects enrolled | United States: 2350 |
| Worldwide total number of subjects | 12280 |
| EEA total number of subjects | 2572 |

Notes:

Subjects enrolled per age group

| | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 5477 |
| From 65 to 84 years | 6634 |
| 85 years and over | 169 |

Subject disposition

Recruitment

Recruitment details:

Prior to initiation of any trial-related procedure, all patients were informed about the trial verbally and in writing by the investigator. The patients signed and dated the informed consent before any study related procedures.

Pre-assignment

Screening details:

All patients were screened for eligibility to participate in the trial. Subjects attended specialist sites which would then ensure that all subjects met all inclusion/exclusion criteria. Subjects were not to be entered to trial treatment if any one of the specific entry criteria were not met.

Period 1

| | |
|------------------------------|----------------------------------|
| Period 1 title | On study period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Blinding implementation details:

Double blind trial

Arms

| | |
|------------------------------|-------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Linagliptin |

Arm description:

Patients were administered Linagliptin 5 milligram (mg) film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve). Five patients were randomised to the Linagliptin arm, however those five patients were not treated. Consequently, number of subjects that started (randomised) is 3499 but only 3494 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

| | |
|--|--------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Linagliptin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Patients were administered Linagliptin 5 milligram (mg) film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve).

| | |
|------------------|---------|
| Arm title | Placebo |
|------------------|---------|

Arm description:

Patients were administered Placebo matching Linagliptin 5 mg film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve). Seven patients were randomised to the placebo arm, however those seven patients were not treated. Consequently, number of subjects that started (randomised) is 3492 but only 3485 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

| | |
|----------|---------|
| Arm type | Placebo |
|----------|---------|

| | |
|--|--------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Patients were administered Placebo matching Linagliptin 5 mg film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve).

| Number of subjects in period 1^[1] | Linagliptin | Placebo |
|---|-------------|---------|
| Started | 3494 | 3485 |
| Completed | 3458 | 3430 |
| Not completed | 36 | 55 |
| Patient lost to follow-up for MACE | 36 | 55 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Not all enrolled subjects were randomized and treated.

Baseline characteristics

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | Linagliptin |
|-----------------------|-------------|

Reporting group description:

Patients were administered Linagliptin 5 milligram (mg) film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve). Five patients were randomised to the Linagliptin arm, however those five patients were not treated. Consequently, number of subjects that started (randomised) is 3499 but only 3494 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Patients were administered Placebo matching Linagliptin 5 mg film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve). Seven patients were randomised to the placebo arm, however those seven patients were not treated. Consequently, number of subjects that started (randomised) is 3492 but only 3485 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

| Reporting group values | Linagliptin | Placebo | Total |
|------------------------|-------------|---------|-------|
| Number of subjects | 3494 | 3485 | 6979 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|--------|--------|------|
| Age Continuous | | | |
| Treated set (TS): All patients treated with at least one dose of trial medication. If no trial medication was taken at site during the visit, but the medication kit was dispensed to the patient and not all trial medication was returned, the patient was included in the TS. | | | |
| Units: years | | | |
| arithmetic mean | 66.1 | 65.6 | |
| standard deviation | ± 9.05 | ± 9.14 | - |
| Sex: Female, Male | | | |
| Treated set (TS): All patients treated with at least one dose of trial medication. If no trial medication was taken at site during the visit, but the medication kit was dispensed to the patient and not all trial medication was returned, the patient was included in the TS. | | | |
| Units: Subjects | | | |
| Female | 1346 | 1243 | 2589 |
| Male | 2148 | 2242 | 4390 |
| Race (NIH/OMB) | | | |
| Treated set (TS): All patients treated with at least one dose of trial medication. If no trial medication was taken at site during the visit, but the medication kit was dispensed to the patient and not all trial medication was returned, the patient was included in the TS. | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 159 | 156 | 315 |
| Asian | 307 | 333 | 640 |
| Native Hawaiian or Other Pacific Islander | 7 | 10 | 17 |
| Black or African American | 194 | 217 | 411 |
| White | 2827 | 2769 | 5596 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Treated set (TS): All patients treated with at least one dose of trial medication. If no trial medication | | | |

was taken at site during the visit, but the medication kit was dispensed to the patient and not all trial medication was returned, the patient was included in the TS.

| Units: Subjects | | | |
|-------------------------|------|------|------|
| Hispanic or Latino | 1227 | 1274 | 2501 |
| Not Hispanic or Latino | 2267 | 2211 | 4478 |
| Unknown or Not Reported | 0 | 0 | 0 |

End points

End points reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | Linagliptin |
|-----------------------|-------------|

Reporting group description:

Patients were administered Linagliptin 5 milligram (mg) film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve). Five patients were randomised to the Linagliptin arm, however those five patients were not treated. Consequently, number of subjects that started (randomised) is 3499 but only 3494 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Patients were administered Placebo matching Linagliptin 5 mg film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve). Seven patients were randomised to the placebo arm, however those seven patients were not treated. Consequently, number of subjects that started (randomised) is 3492 but only 3485 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

Primary: Time to the first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint 3-point major adverse cardiovascular (CV) events (3-point MACE): CV death, non-fatal myocardial infarction (MI) or non-fatal stroke.

| | |
|-----------------|---|
| End point title | Time to the first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint 3-point major adverse cardiovascular (CV) events (3-point MACE): CV death, non-fatal myocardial infarction (MI) or non-fatal stroke. |
|-----------------|---|

End point description:

Time to the first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint 3-point major adverse cardiovascular (CV) events (3-point MACE): CV death, non-fatal myocardial infarction (MI) or non-fatal stroke. The percentage of observed patients with first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint (3-point MACE) was reported.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From randomization to individual end of observation; up to 4.3 years

| End point values | Linagliptin | Placebo | | |
|-----------------------------------|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3494 ^[1] | 3485 ^[2] | | |
| Units: percentage of participants | | | | |
| number (not applicable) | 12.4 | 12.1 | | |

Notes:

[1] - TS

[2] - TS

Statistical analyses

| | |
|--|--------------------------------|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: | |
| Cox proportional hazard regression model was performed to compare the effect of linagliptin versus placebo. Model included randomised treatment and geographical region as factors. Breslow's method was used for dealing with ties. First hypothesis (non-inferiority of the primary endpoint) was to be tested at the one-sided alpha-level of 2.5%. In case of significance the next set of hypotheses (two separate hypothesis tests) were to be tested with a sequentially rejective multiple test procedure. | |
| Comparison groups | Linagliptin v Placebo |
| Number of subjects included in analysis | 6979 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[3] |
| P-value | = 0.0002 ^[4] |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.89 |
| upper limit | 1.17 |

Notes:

[3] - The non-inferiority margin was chosen as 1.3 (FDA Guidance for Industry - Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes).

[4] - p-value for Hazard ratio (HR) ≥ 1.3 (1-sided). Based on a Cox regression model with terms for treatment group and region.

| | |
|--|-------------------------|
| Statistical analysis title | Statistical Analysis 2 |
| Statistical analysis description: | |
| Cox proportional hazard regression model was performed to compare the effect of linagliptin versus placebo. Model included randomised treatment and geographical region as factors. Breslow's method was used for dealing with ties. First hypothesis (non-inferiority of the primary endpoint) was to be tested at the one-sided alpha-level of 2.5%. In case of significance the next set of hypotheses (two separate hypothesis tests) were to be tested with a sequentially rejective multiple test procedure. | |
| Comparison groups | Linagliptin v Placebo |
| Number of subjects included in analysis | 6979 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.6301 ^[5] |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.89 |
| upper limit | 1.17 |

Notes:

[5] - p-value for HR ≥ 1.0 (1-sided). Based on a Cox regression model with terms for treatment group and region.

Secondary: Time to the first occurrence of any of the following adjudication-confirmed components: renal death, sustained End Stage Renal Disease (ESRD), or sustained decrease of 40% or more in Estimated Glomerular Filtration Rate (eGFR).

| | |
|-----------------|---|
| End point title | Time to the first occurrence of any of the following adjudication-confirmed components: renal death, sustained End Stage Renal Disease (ESRD), or sustained decrease of |
|-----------------|---|

End point description:

Time to the first occurrence of any of the following adjudication-confirmed components: renal death, sustained ESRD, or sustained decrease of 40% or more in eGFR. The percentage of observed patients with first occurrence of any of the following adjudication-confirmed components: renal death, sustained ESRD, or sustained decrease of 40% or more in eGFR was reported.

End point type

Secondary

End point timeframe:

From randomization to individual end of observation; up to 4.3 years

| End point values | Linagliptin | Placebo | | |
|-----------------------------------|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3494 ^[6] | 3485 ^[7] | | |
| Units: percentage of participants | | | | |
| number (not applicable) | 9.4 | 8.8 | | |

Notes:

[6] - TS

[7] - TS

Statistical analyses

Statistical analysis title

Statistical Analysis 1

Statistical analysis description:

Cox proportional hazard regression model was performed to compare the effect of linagliptin versus placebo. Model included randomised treatment and geographical region as factors. Breslow's method was used for dealing with ties. First hypothesis (non-inferiority of the primary endpoint) was to be tested at the one-sided alpha-level of 2.5%. In case of significance the next set of hypotheses (two separate hypothesis tests) were to be tested with a sequentially rejective multiple test procedure.

| | |
|---|-------------------------|
| Comparison groups | Linagliptin v Placebo |
| Number of subjects included in analysis | 6979 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.6918 ^[8] |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.89 |
| upper limit | 1.22 |

Notes:

[8] - p-value for HR ≥ 1.0 (1-sided). Based on a Cox regression model with terms for treatment group and region.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events with an onset after the first dose of trial medication up to a period of 7 days after the last permanent study drug stop; up to 4.3 years.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 20.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | Linagliptin |
|-----------------------|-------------|

Reporting group description:

Patients were administered Linagliptin 5 milligram (mg) film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve).

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Patients were administered Placebo matching Linagliptin 5 mg film-coated tablet orally once daily. At Visit 2, patients received one treatment box sufficient for 12 weeks treatment (plus 1 week reserve). At Visit 3 (until trial end) patients received 2 medication boxes sufficient for 24 weeks treatment (plus 2 weeks reserve).

| Serious adverse events | Linagliptin | Placebo | |
|---|----------------------|----------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1293 / 3494 (37.01%) | 1343 / 3485 (38.54%) | |
| number of deaths (all causes) | 367 | 373 | |
| number of deaths resulting from adverse events | 250 | 253 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute monocytic leukaemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Acute promyelocytic leukaemia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma gastric | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Adenocarcinoma pancreas | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 14 / 3494 (0.40%) | 14 / 3485 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 17 | 0 / 15 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Basosquamous carcinoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Basosquamous carcinoma of skin | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign breast neoplasm | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign ovarian tumour | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder cancer | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder neoplasm | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bowen's disease | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain neoplasm | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Bronchial carcinoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cancer | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cancer pain | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carcinoma in situ of penis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac myxoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac neoplasm unspecified | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervix carcinoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest wall tumour | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholesteatoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon adenoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon cancer | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Colon neoplasm | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Diffuse large b-cell lymphoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial adenocarcinoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gallbladder cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric adenoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric cancer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal cancer metastatic | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal neoplasm | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Hepatic neoplasm | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatocellular carcinoma | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hodgkin's disease | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intraductal proliferative breast lesion | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Invasive ductal breast carcinoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngeal cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leiomyosarcoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lip neoplasm malignant stage unspecified | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | |
| Lung adenocarcinoma stage 0 | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung cancer metastatic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm malignant | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 7 / 3494 (0.20%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 5 | 0 / 2 | |
| Lymphoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Malignant anorectal neoplasm | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Malignant melanoma in situ | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant pleural effusion | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Mediastinum neoplasm | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningioma | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to bone | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Metastases to liver | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Metastases to lung | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Metastases to spine | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic carcinoma of the bladder | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Metastatic malignant melanoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Mucinous cystadenocarcinoma of pancreas | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myelodysplastic syndrome | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Myeloproliferative neoplasm | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Naevoid melanoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuroendocrine tumour | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasm skin | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-small cell lung cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal adenocarcinoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal carcinoma recurrent | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal carcinoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Pancreatic carcinoma metastatic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic neoplasm | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Papillary renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Papillary thyroid cancer | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Penile squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Plasma cell myeloma | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 9 / 3494 (0.26%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 9 | 1 / 8 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Plasmacytoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostatic adenoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer metastatic | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal adenoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal adenocarcinoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cancer | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Rectal cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Renal cell carcinoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal neoplasm | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Schwannoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sebaceous adenoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small cell lung cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Squamous cell carcinoma of lung | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 8 / 3494 (0.23%) | 9 / 3485 (0.26%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Testis cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tongue cancer recurrent | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tongue neoplasm malignant stage unspecified | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transitional cell cancer of the renal pelvis and ureter | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tumour of ampulla of vater | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vulval cancer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vulval cancer stage 0 | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |

| | | | |
|---|------------------|------------------|--|
| Accelerated hypertension | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angiopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Aortic aneurysm rupture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Aortic stenosis | | | |
| subjects affected / exposed | 8 / 3494 (0.23%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic thrombosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arterial insufficiency | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arterial rupture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriosclerosis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Arteriovenous fistula | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood pressure inadequately controlled | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Circulatory collapse | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 12 / 3494 (0.34%) | 14 / 3485 (0.40%) | |
| occurrences causally related to treatment / all | 1 / 12 | 0 / 15 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Diabetic macroangiopathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic vascular disorder | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Distributive shock | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Dry gangrene | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Embolism | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Embolism venous | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Embolism arterial | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femoral artery aneurysm | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Extremity necrosis | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 9 / 3485 (0.26%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertension | | | |
| subjects affected / exposed | 32 / 3494 (0.92%) | 18 / 3485 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 32 | 0 / 19 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Hypertensive crisis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 16 / 3494 (0.46%) | 20 / 3485 (0.57%) | |
| occurrences causally related to treatment / all | 0 / 18 | 0 / 22 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive emergency | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypovolaemic shock | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | |
| Intermittent claudication | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iliac artery occlusion | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Orthostatic hypertension | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 18 / 3494 (0.52%) | 17 / 3485 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 23 | 1 / 17 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Orthostatic hypotension | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 6 / 3494 (0.17%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery occlusion | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 12 / 3485 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery thrombosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral embolism | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 11 / 3485 (0.32%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral vascular disorder | | | |
| subjects affected / exposed | 6 / 3494 (0.17%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral venous disease | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Shock | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subclavian artery stenosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systolic hypertension | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombophlebitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular insufficiency | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Varicose ulceration | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vein rupture | | | |

| | | | |
|--|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Coronary revascularisation | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hospitalisation | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral endarterectomy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Application site haemorrhage | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Asthenia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac death | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 1 / 7 | 1 / 5 | |
| deaths causally related to treatment / all | 1 / 7 | 1 / 5 | |

| | | | |
|---|-------------------|-------------------|--|
| Catheter site haemorrhage | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest discomfort | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest pain | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chills | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic fatigue syndrome | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Complication associated with device | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Death | | | |
| subjects affected / exposed | 16 / 3494 (0.46%) | 23 / 3485 (0.66%) | |
| occurrences causally related to treatment / all | 0 / 16 | 0 / 23 | |
| deaths causally related to treatment / all | 0 / 16 | 0 / 23 | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Feeling abnormal | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General physical health deterioration | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Generalised oedema | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Impaired healing | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injection site haematoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malaise | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Medical device site joint inflammation | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Necrobiosis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 15 / 3494 (0.43%) | 15 / 3485 (0.43%) | |
| occurrences causally related to treatment / all | 0 / 16 | 0 / 16 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Strangulated hernia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sudden cardiac death | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 3 | |
| Sudden death | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 20 / 3485 (0.57%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 20 | |
| deaths causally related to treatment / all | 0 / 10 | 0 / 20 | |
| Systemic inflammatory response syndrome | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ulcer haemorrhage | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular stent occlusion | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular stent restenosis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypersensitivity | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Overlap syndrome | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Social circumstances | | | |
| Homicide | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Limb prosthesis user | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Acquired hydrocele | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acquired phimosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical polyp | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystocele | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial hypertrophy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhagic ovarian cyst | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine polyp | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal leukoplakia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute pulmonary oedema | | | |
| subjects affected / exposed | 13 / 3494 (0.37%) | 15 / 3485 (0.43%) | |
| occurrences causally related to treatment / all | 1 / 16 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Acute respiratory distress syndrome | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 9 / 3494 (0.26%) | 11 / 3485 (0.32%) | |
| occurrences causally related to treatment / all | 1 / 12 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Asphyxia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Aspiration | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Asthma | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 3 / 3494 (0.09%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atelectasis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis chronic | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchospasm | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 21 / 3494 (0.60%) | 28 / 3485 (0.80%) | |
| occurrences causally related to treatment / all | 0 / 28 | 0 / 38 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | |
| Chronic respiratory failure | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cough | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 16 / 3494 (0.46%) | 16 / 3485 (0.46%) | |
| occurrences causally related to treatment / all | 1 / 16 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Dyspnoea exertional | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Emphysema | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eosinophilic pneumonia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epistaxis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemothorax | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoxia | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Interstitial lung disease | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung disorder | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngeal oedema | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mendelson's syndrome | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mediastinal mass | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraneoplastic pleural effusion | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 11 / 3485 (0.32%) | |
| occurrences causally related to treatment / all | 0 / 6 | 1 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Pleural thickening | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pneumonitis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Portopulmonary hypertension | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 9 / 3494 (0.26%) | 12 / 3485 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | |
| Pulmonary congestion | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary fibrosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 12 / 3494 (0.34%) | 14 / 3485 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 14 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary oedema | | | |
| subjects affected / exposed | 16 / 3494 (0.46%) | 13 / 3485 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 17 | 1 / 13 | |
| deaths causally related to treatment / all | 0 / 1 | 1 / 2 | |
| Pulmonary mass | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory arrest | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory distress | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Respiratory failure | | | |
| subjects affected / exposed | 13 / 3494 (0.37%) | 14 / 3485 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 14 | |
| deaths causally related to treatment / all | 0 / 5 | 0 / 2 | |
| Sinus polyp | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Restrictive pulmonary disease | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vocal cord cyst | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sleep apnoea syndrome | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vocal cord disorder | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vocal cord polyp | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wheezing | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Acute stress disorder | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adjustment disorder | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Affect lability | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Confusional state | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Delirium | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Depression | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Drug use disorder | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hallucination, visual | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Irritability | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Major depression | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mental status changes | | | |

| | | | |
|--|------------------|------------------|--|
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mood disorder due to a general medical condition | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychotic disorder | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Product issues | | | |
| Device failure | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device malfunction | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Autoimmune hepatitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bile duct obstruction | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-------------------|------------------|--|
| Bile duct stone | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary colic | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary dyspepsia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary tract disorder | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholangitis acute | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 1 / 10 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis chronic | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholelithiasis | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 9 / 3485 (0.26%) | |
| occurrences causally related to treatment / all | 0 / 10 | 1 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cirrhosis alcoholic | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cirrhosis | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic failure | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Hepatic steatosis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic hepatitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jaundice | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Portal hypertension | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriogram coronary | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aspiration bronchial | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood glucose increased | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood pressure increased | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Catheterisation cardiac | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Creatinine renal clearance decreased | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Echocardiogram | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ejection fraction decreased | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Electrocardiogram qt prolonged | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Electrocardiogram t wave inversion | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 36 / 3494 (1.03%) | 30 / 3485 (0.86%) | |
| occurrences causally related to treatment / all | 0 / 42 | 0 / 33 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glycosylated haemoglobin increased | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza a virus test positive | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracardiac pressure increased | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lipase increased | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 3 / 4 | 2 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver function test increased | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostatic specific antigen increased | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcus test positive | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Troponin increased | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urine output decreased | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Anastomotic complication | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Animal bite | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ankle fracture | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arterial bypass occlusion | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriovenous fistula site complication | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriovenous fistula thrombosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back injury | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bone contusion | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain contusion | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Burns second degree | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carbon monoxide poisoning | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical vertebral fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest injury | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon injury | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Contusion | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery restenosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Craniocerebral injury | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Endotracheal intubation complication | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial bones fracture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fall | | | |
| subjects affected / exposed | 19 / 3494 (0.54%) | 25 / 3485 (0.72%) | |
| occurrences causally related to treatment / all | 0 / 19 | 1 / 25 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femur fracture | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 10 / 3494 (0.29%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fibula fracture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Foot fracture | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fracture displacement | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Head injury | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Heart injury | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hip fracture | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Humerus fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 3494 (0.09%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyphaema | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incisional hernia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incomplete spinal fusion | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jaw fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint dislocation | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint injury | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laceration | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb crushing injury | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb injury | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower limb fracture | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar vertebral fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple injuries | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle injury | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Overdose | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Patella fracture | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic fracture | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Periprocedural myocardial infarction | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Periprosthetic fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritoneal dialysis complication | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax traumatic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural complication | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural haemorrhage | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative delirium | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative respiratory distress | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Procedural hypotension | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Procedural intestinal perforation | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Radius fracture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rib fracture | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Road traffic accident | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Scar | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skeletal injury | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Skull fractured base | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal compression fracture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Splenic rupture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sternal fracture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stoma site polyp | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stomal hernia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Subdural haematoma | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tendon rupture | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tibia fracture | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic intracranial haemorrhage | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic liver injury | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ulna fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper limb fracture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular pseudoaneurysm | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vith nerve injury | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound dehiscence | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound necrosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wrist fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Congenital, familial and genetic disorders | | | |
| Accessory spleen | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial septal defect | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystic lymphangioma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dermoid cyst | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal arteriovenous malformation | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertrophic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Keratosis follicular | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial bridging | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 12 / 3494 (0.34%) | 18 / 3485 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 17 | 2 / 19 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Acute left ventricular failure | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 78 / 3494 (2.23%) | 59 / 3485 (1.69%) | |
| occurrences causally related to treatment / all | 6 / 101 | 5 / 70 | |
| deaths causally related to treatment / all | 4 / 17 | 1 / 10 | |
| Adams-stokes syndrome | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina pectoris | | | |
| subjects affected / exposed | 42 / 3494 (1.20%) | 25 / 3485 (0.72%) | |
| occurrences causally related to treatment / all | 1 / 51 | 0 / 34 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina unstable | | | |
| subjects affected / exposed | 77 / 3494 (2.20%) | 70 / 3485 (2.01%) | |
| occurrences causally related to treatment / all | 6 / 84 | 1 / 77 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve disease | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve incompetence | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arrhythmia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Arrhythmia supraventricular | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriosclerosis coronary artery | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 34 / 3494 (0.97%) | 26 / 3485 (0.75%) | |
| occurrences causally related to treatment / all | 0 / 37 | 0 / 28 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Atrial flutter | | | |
| subjects affected / exposed | 13 / 3494 (0.37%) | 11 / 3485 (0.32%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block complete | | | |
| subjects affected / exposed | 9 / 3494 (0.26%) | 10 / 3485 (0.29%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block first degree | | | |

| | | | |
|---|--------------------|--------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block second degree | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bradycardia | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bundle branch block left | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac arrest | | | |
| subjects affected / exposed | 25 / 3494 (0.72%) | 17 / 3485 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 25 | 1 / 17 | |
| deaths causally related to treatment / all | 0 / 23 | 1 / 15 | |
| Cardiac disorder | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cardiac failure | | | |
| subjects affected / exposed | 104 / 3494 (2.98%) | 104 / 3485 (2.98%) | |
| occurrences causally related to treatment / all | 3 / 148 | 3 / 141 | |
| deaths causally related to treatment / all | 3 / 14 | 1 / 10 | |
| Cardiac failure acute | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | |
| Cardiac failure chronic | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 24 / 3494 (0.69%) | 20 / 3485 (0.57%) | |
| occurrences causally related to treatment / all | 0 / 30 | 0 / 28 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 77 / 3494 (2.20%) | 98 / 3485 (2.81%) | |
| occurrences causally related to treatment / all | 10 / 102 | 5 / 153 | |
| deaths causally related to treatment / all | 1 / 6 | 0 / 3 | |
| Cardiac tamponade | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardio-respiratory arrest | | | |
| subjects affected / exposed | 8 / 3494 (0.23%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 7 | 0 / 7 | |
| Cardiogenic shock | | | |
| subjects affected / exposed | 8 / 3494 (0.23%) | 12 / 3485 (0.34%) | |
| occurrences causally related to treatment / all | 3 / 8 | 1 / 12 | |
| deaths causally related to treatment / all | 2 / 6 | 1 / 12 | |
| Cardiomegaly | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cardiomyopathy | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cardiomyopathy acute | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiopulmonary failure | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 1 | |
| Cardiorenal syndrome | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiovascular disorder | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiovascular insufficiency | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 1 / 2 | 0 / 1 | |
| Chordae tendinae rupture | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic left ventricular failure | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Conduction disorder | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease | | | |
| subjects affected / exposed | 26 / 3494 (0.74%) | 21 / 3485 (0.60%) | |
| occurrences causally related to treatment / all | 3 / 27 | 1 / 23 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Coronary artery occlusion | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 6 / 3494 (0.17%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 1 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 9 | 1 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cyanosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Degenerative mitral valve disease | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diastolic dysfunction | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracardiac thrombus | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Left ventricular dysfunction | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Left ventricular failure | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 13 / 3494 (0.37%) | 12 / 3485 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 13 | 0 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Mitral valve disease | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve stenosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial fibrosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 47 / 3494 (1.35%) | 54 / 3485 (1.55%) | |
| occurrences causally related to treatment / all | 1 / 49 | 3 / 64 | |
| deaths causally related to treatment / all | 1 / 14 | 0 / 8 | |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 20 / 3494 (0.57%) | 12 / 3485 (0.34%) | |
| occurrences causally related to treatment / all | 1 / 20 | 1 / 14 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 1 | |
| Myocardial necrosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocarditis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paroxysmal atrioventricular block | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericardial effusion | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pericarditis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericarditis constrictive | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulseless electrical activity | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Silent myocardial infarction | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus arrest | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus bradycardia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus node dysfunction | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus tachycardia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systolic dysfunction | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tachyarrhythmia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tricuspid valve incompetence | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Trifascicular block | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular arrhythmia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nervous system disorders | | | |
| Altered state of consciousness | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Basal ganglia infarction | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain injury | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Brain oedema | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Brain stem infarction | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid arteriosclerosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery dissection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery occlusion | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid sinus syndrome | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Central nervous system lesion | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral haematoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cerebral infarction | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral ischaemia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral small vessel ischaemic disease | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrospinal fluid leakage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 12 / 3485 (0.34%) | |
| occurrences causally related to treatment / all | 1 / 11 | 0 / 13 | |
| deaths causally related to treatment / all | 1 / 4 | 0 / 3 | |
| Cerebrovascular disorder | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical radiculopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervicobrachial syndrome | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Complex regional pain syndrome | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dementia | | | |
| subjects affected / exposed | 8 / 3494 (0.23%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 8 | 1 / 6 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Dementia with lewy bodies | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic coma | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 1 / 2 | 0 / 1 | |
| Diabetic neuropathy | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 7 / 3494 (0.20%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dizziness | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyskinesia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Embololic stroke | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Encephalopathy | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epilepsy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial nerve disorder | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial paralysis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Generalised tonic-clonic seizure | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 1 / 3 | 0 / 1 | |
| Haemorrhagic stroke | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 1 / 10 | 0 / 8 | |
| deaths causally related to treatment / all | 1 / 5 | 0 / 5 | |
| Headache | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemiplegia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic encephalopathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hypertensive encephalopathy | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemic coma | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoxic-ischaemic encephalopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incoherent | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracranial pressure increased | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracranial aneurysm | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intraventricular haemorrhage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic cerebral infarction | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 61 / 3494 (1.75%) | 49 / 3485 (1.41%) | |
| occurrences causally related to treatment / all | 5 / 63 | 2 / 53 | |
| deaths causally related to treatment / all | 2 / 9 | 1 / 4 | |
| Lacunar infarction | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lacunar stroke | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Loss of consciousness | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar radiculopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolic encephalopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple sclerosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myasthenia gravis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myelopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuritis cranial | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuroglycopenia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parkinson's disease | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parkinsonism | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Partial seizures | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polyneuropathy | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post stroke seizure | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Presyncope | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sciatica | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seizure | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal claudication | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal cord compression | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal epidural haematoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 15 / 3494 (0.43%) | 25 / 3485 (0.72%) | |
| occurrences causally related to treatment / all | 0 / 15 | 1 / 28 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thalamic infarction | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombotic stroke | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 27 / 3494 (0.77%) | 9 / 3485 (0.26%) | |
| occurrences causally related to treatment / all | 0 / 29 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tremor | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uraemic encephalopathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular headache | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebrobasilar insufficiency | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vith nerve paralysis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wernicke's encephalopathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 19 / 3494 (0.54%) | 17 / 3485 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 30 | 0 / 17 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anaemia macrocytic | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anaemia of malignant disease | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Autoimmune haemolytic anaemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eosinophilia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhagic anaemia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypochromic anaemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune thrombocytopenic purpura | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leukocytosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphadenitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrogenic anaemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancytopenia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ear and labyrinth disorders | | | |
| Conductive deafness | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness bilateral | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness neurosensory | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness unilateral | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoacusis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sudden hearing loss | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertigo | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertigo positional | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Acquired corneal dystrophy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Amaurosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Amaurosis fugax | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angle closure glaucoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blindness | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blindness unilateral | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cataract | | | |
| subjects affected / exposed | 11 / 3494 (0.31%) | 13 / 3485 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 13 | 0 / 17 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cataract cortical | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Corneal decompensation | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystoid macular oedema | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic retinal oedema | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diplopia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dry age-related macular degeneration | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glaucoma | | | |
| subjects affected / exposed | 6 / 3494 (0.17%) | 9 / 3485 (0.26%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyalosis asteroid | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular degeneration | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular fibrosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular hole | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 4 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular oedema | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neovascular age-related macular degeneration | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Open angle glaucoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal artery embolism | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal artery occlusion | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal degeneration | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal detachment | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal vein occlusion | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ulcerative keratitis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uveitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vitreous haematoma | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vitreous haemorrhage | | | |
| subjects affected / exposed | 6 / 3494 (0.17%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal adhesions | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal hernia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal hernia obstructive | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 1 / 5 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal tenderness | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal wall haematoma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal fissure | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal fistula | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal polyp | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ascites | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Barrett's oesophagus | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic gastritis | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis ischaemic | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Constipation | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic gastroparesis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 9 / 3494 (0.26%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulum | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulum intestinal | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulum intestinal haemorrhagic | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenal perforation | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenal ulcer | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenal vascular ectasia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenitis haemorrhagic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysphagia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enteritis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterocolitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterocolitis haemorrhagic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterovesical fistula | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Faecaloma | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric antral vascular ectasia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric haemorrhage | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric polyps | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric ulcer | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric ulcer perforation | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 8 / 3485 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 5 | 1 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis erosive | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis haemorrhagic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroduodenal ulcer | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 9 / 3494 (0.26%) | 11 / 3485 (0.32%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Gastrointestinal necrosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Gastrointestinal obstruction | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Gastrointestinal perforation | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematemesis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematochezia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hiatus hernia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ileus | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incarcerated inguinal hernia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Inguinal hernia | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal obstruction | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Intestinal perforation | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal polyp | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestinal obstruction | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestine polyp | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lip ulceration | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mechanical ileus | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Melaena | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mesenteric artery thrombosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Mesenteric haemorrhage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Obstructive pancreatitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oedema mouth | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal varices haemorrhage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic cyst | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic failure | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 6 / 3494 (0.17%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 3 / 6 | 2 / 3 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Pancreatitis acute | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 7 / 3494 (0.20%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 2 / 7 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pancreatitis chronic | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 2 | 2 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peptic ulcer | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritoneal adhesions | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal polyp | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retroperitoneal fibrosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Strangulated umbilical hernia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tongue oedema | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Umbilical hernia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 8 / 3494 (0.23%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 6 / 3494 (0.17%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting projectile | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Decubitus ulcer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dermal cyst | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dermatitis bullous | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dermatitis exfoliative generalised | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic foot | | | |
| subjects affected / exposed | 21 / 3494 (0.60%) | 24 / 3485 (0.69%) | |
| occurrences causally related to treatment / all | 0 / 27 | 0 / 28 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ichthyosis acquired | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic skin ulcer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lentigo | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Necrobiosis lipidica diabetorum | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neurodermatitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pemphigoid | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pruritus | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rash | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin necrosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin ulcer | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 10 / 3485 (0.29%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin ulcer haemorrhage | | | |

| | | | |
|---|-------------------|--------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stasis dermatitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Swelling face | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Toxic epidermal necrolysis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 96 / 3494 (2.75%) | 100 / 3485 (2.87%) | |
| occurrences causally related to treatment / all | 4 / 109 | 1 / 111 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | |
| Acute prerenal failure | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anuria | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder prolapse | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Azotaemia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Calculus bladder | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic kidney disease | | | |
| subjects affected / exposed | 49 / 3494 (1.40%) | 32 / 3485 (0.92%) | |
| occurrences causally related to treatment / all | 2 / 56 | 1 / 35 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Diabetic nephropathy | | | |
| subjects affected / exposed | 9 / 3494 (0.26%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| End stage renal disease | | | |
| subjects affected / exposed | 38 / 3494 (1.09%) | 45 / 3485 (1.29%) | |
| occurrences causally related to treatment / all | 3 / 39 | 0 / 49 | |
| deaths causally related to treatment / all | 1 / 3 | 0 / 2 | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glomerulonephritis membranous | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematuria | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydronephrosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 4 / 3494 (0.11%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive nephropathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mesangioproliferative glomerulonephritis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 1 / 6 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephropathy | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephropathy toxic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 8 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oliguria | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Proteinuria | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal colic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal artery stenosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal disorder | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 32 / 3494 (0.92%) | 31 / 3485 (0.89%) | |
| occurrences causally related to treatment / all | 2 / 32 | 2 / 33 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 1 | |
| Renal mass | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal impairment | | | |
| subjects affected / exposed | 24 / 3494 (0.69%) | 27 / 3485 (0.77%) | |
| occurrences causally related to treatment / all | 2 / 26 | 1 / 29 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Renal tubular necrosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal pain | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ureterolithiasis | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tubulointerstitial nephritis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral haemorrhage | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary retention | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adrenal mass | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Goitre | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperthyroidism | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thyroid mass | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Ankylosing spondylitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis reactive | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back pain | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bone pain | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bursitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic arthropathy | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Exostosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fibromyalgia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gouty arthritis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc degeneration | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc disorder | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb discomfort | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle haemorrhage | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal chest pain | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 3 / 3494 (0.09%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myopathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myopathy toxic | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neck pain | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuropathic arthropathy | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 15 / 3494 (0.43%) | 17 / 3485 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 19 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteochondrosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteonecrosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pathological fracture | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Periostitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Plantar fasciitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polymyalgia rheumatica | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rheumatoid arthritis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal column stenosis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal pain | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spondylolisthesis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Synovial cyst | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systemic lupus erythematosus | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebral osteophyte | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Abdominal abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal sepsis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Abdominal wall abscess | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abscess limb | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis bacterial | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacteraemia | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacterial infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacterial pyelonephritis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacterial sepsis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blebitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 8 / 3494 (0.23%) | 17 / 3485 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 17 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bursitis infective | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carbuncle | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Catheter site infection | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 22 / 3494 (0.63%) | 38 / 3485 (1.09%) | |
| occurrences causally related to treatment / all | 0 / 23 | 0 / 42 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Chikungunya virus infection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis infective | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium colitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cytomegalovirus infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dengue fever | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related infection | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related sepsis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Diabetic foot infection | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic gangrene | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Disseminated tuberculosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulitis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis bacterial | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enteritis infectious | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epididymitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Erysipelas | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fungal peritonitis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gangrene | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 14 / 3485 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 13 | 0 / 15 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 11 / 3494 (0.31%) | 9 / 3485 (0.26%) | |
| occurrences causally related to treatment / all | 0 / 11 | 1 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis norovirus | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis shigella | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal bacterial infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal viral infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Graft infection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Groin abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| H1n1 influenza | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis c | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis infectious mononucleosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes zoster | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Histoplasmosis cutaneous | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Histoplasmosis disseminated | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infected cyst | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infected dermal cyst | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infected skin ulcer | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infection | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infectious colitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infective exacerbation of chronic obstructive airways disease | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injection site abscess | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral discitis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal sepsis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Klebsiella bacteraemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Klebsiella infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Klebsiella sepsis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leptospirosis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver abscess | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Localised infection | | | |
| subjects affected / exposed | 10 / 3494 (0.29%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lung infection | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lyme disease | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mediastinitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Medical device site cellulitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis viral | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mycoplasma infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myiasis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Necrotising fasciitis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Neutropenic sepsis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nosocomial infection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Orchitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteomyelitis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 11 / 3494 (0.31%) | 14 / 3485 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 15 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteomyelitis chronic | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteomyelitis viral | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Otitis media | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paronychia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Perineal abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Periodontitis | | | |

| | | | |
|---|-------------------|--------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonitis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Peritonitis bacterial | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 99 / 3494 (2.83%) | 121 / 3485 (3.47%) | |
| occurrences causally related to treatment / all | 0 / 114 | 1 / 139 | |
| deaths causally related to treatment / all | 0 / 5 | 0 / 10 | |
| Pneumonia bacterial | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia chlamydial | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia klebsiella | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia legionella | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia pneumococcal | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative wound infection | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pseudomembranous colitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pseudomonas infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary sepsis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulpitis dental | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 14 / 3494 (0.40%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 18 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 6 / 3494 (0.17%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 1 / 7 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis chronic | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Scrotal abscess | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Scrub typhus | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 18 / 3494 (0.52%) | 33 / 3485 (0.95%) | |
| occurrences causally related to treatment / all | 1 / 18 | 0 / 34 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 11 | |
| Septic shock | | | |
| subjects affected / exposed | 13 / 3494 (0.37%) | 12 / 3485 (0.34%) | |
| occurrences causally related to treatment / all | 1 / 13 | 1 / 12 | |
| deaths causally related to treatment / all | 0 / 8 | 0 / 8 | |
| Sialoadenitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin infection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Soft tissue infection | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal cord abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal infection | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Streptococcal bacteraemia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systemic infection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tracheobronchitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tuberculosis | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 30 / 3494 (0.86%) | 41 / 3485 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 35 | 0 / 44 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection bacterial | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection fungal | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection pseudomonal | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Viraemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral tonsillitis | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound infection | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 2 / 3485 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Abnormal loss of weight | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acquired mixed hyperlipidaemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dehydration | | | |
| subjects affected / exposed | 11 / 3494 (0.31%) | 6 / 3485 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 9 / 3494 (0.26%) | 7 / 3485 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 10 / 3485 (0.29%) | |
| occurrences causally related to treatment / all | 1 / 7 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetes with hyperosmolarity | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 4 / 3485 (0.11%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic metabolic decompensation | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 10 / 3494 (0.29%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 1 / 10 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Failure to thrive | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fluid imbalance | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fluid overload | | | |
| subjects affected / exposed | 5 / 3494 (0.14%) | 11 / 3485 (0.32%) | |
| occurrences causally related to treatment / all | 1 / 6 | 1 / 14 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fluid retention | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gout | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperglycaemia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 12 / 3494 (0.34%) | 22 / 3485 (0.63%) | |
| occurrences causally related to treatment / all | 1 / 12 | 2 / 24 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 16 / 3494 (0.46%) | 19 / 3485 (0.55%) | |
| occurrences causally related to treatment / all | 0 / 16 | 0 / 21 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Hyperlipasaemia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperosmolar state | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypocalcaemia | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperuricaemia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemia | | | |
| subjects affected / exposed | 28 / 3494 (0.80%) | 38 / 3485 (1.09%) | |
| occurrences causally related to treatment / all | 15 / 40 | 20 / 47 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 3 / 3494 (0.09%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 6 / 3494 (0.17%) | 5 / 3485 (0.14%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypovolaemia | | | |
| subjects affected / exposed | 0 / 3494 (0.00%) | 3 / 3485 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lactic acidosis | | | |
| subjects affected / exposed | 2 / 3494 (0.06%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolic acidosis | | | |
| subjects affected / exposed | 7 / 3494 (0.20%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 1 | |
| Obesity | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3494 (0.00%) | 1 / 3485 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 4 / 3494 (0.11%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vitamin d deficiency | | | |
| subjects affected / exposed | 1 / 3494 (0.03%) | 0 / 3485 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Linagliptin | Placebo | |
|---|----------------------|----------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1434 / 3494 (41.04%) | 1422 / 3485 (40.80%) | |
| Investigations | | | |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 202 / 3494 (5.78%) | 200 / 3485 (5.74%) | |
| occurrences (all) | 248 | 251 | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 216 / 3494 (6.18%) | 232 / 3485 (6.66%) | |
| occurrences (all) | 255 | 273 | |
| Infections and infestations | | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 196 / 3494 (5.61%) | 162 / 3485 (4.65%) | |
| occurrences (all) | 267 | 218 | |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 208 / 3494 (5.95%) | 240 / 3485 (6.89%) | |
| occurrences (all) | 975 | 917 | |
| Hypoglycaemia | | | |

| | | | |
|-----------------------------|-------------------------|-------------------------|--|
| subjects affected / exposed | 1022 / 3494 (29.25%) | 1003 / 3485 (28.78%) | |
| occurrences (all) | 6434 | 7206 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 24 October 2013 | Renal composite 2 endpoint (renal death, sustained ESRD, sustained decrease of 40% or more in eGFR) added as tertiary endpoint (This tertiary endpoint was then with amendment No.2 (22 Nov 2016) elevated to become key secondary endpoint) |
| 22 November 2016 | - Number of patients with primary endpoint events decreased from 625 to 611 and estimated treatment period increased from 48 to 54 months. Since the interim analysis for efficacy was removed from the protocol, the required number of patients with primary endpoint to achieve a power of 90% for non-inferiority is reduced from 625 to 611. The estimated trial duration increased slightly due to the change of the primary endpoint while ensuring a sufficiently long drug exposure for the last recruited patients. - The primary endpoint changed from 4-point MACE to 3-point MACE in line with advice by the independent Steering Committee of the trial based on the review of recently published cardiovascular outcome trials (and 3-point MACE removed from key secondary endpoints). 4-point MACE became a tertiary endpoint. -The eGFR cut off in the key secondary endpoint 'composite renal endpoint (renal death, sustained ESRD, sustained decrease of 50% or more in eGFR)' was changed to 40% in response to the National Institutes of Health (NIH) / Food and Drug Administration (FDA) scientific workshop on GFR decline as an endpoint for clinical trials in chronic kidney disease (CKD), and the current clinical landscape on decline in eGFR and subsequent risk of end stage renal disease and mortality. - The formal confirmatory interim analysis was removed. - The hypothesis testing was changed, with a higher alpha-level assigned to the composite renal endpoint. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported